A phase II study of imatinib and docetaxel in metastatic hormone refractory prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Imatinib (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 10 Dec 2012 Planned End Date changed from 1 May 2012 to 1 May 2014 as reported by ClinicalTrials.gov.